OBJECTIVE: To observe the effect and explore the action mechanism of Danhong Injection (DHI) on serum levels of endothelin-1 (ET-1), soluble P-selectin (sP-sel) and high sensitivity C-reactive protein (hs-CRP) in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). METHODS:Seventy ACS patients scheduled to receivePCI were assigned to two groups. Around PCI, the 34 patients in the control group were treated with conventional therapy and the 36 in the DHI group treated with conventional therapy combined with DHI treatment given from the day of PCI to the 14th day after operation at the dose of 40 mL per day by dissolving in 250 mL of 5% glucose for venous dripping. Plasma levels of ET-1, sP-sel and hs-CRP were detected using ELISA at various time points: before PCI (T0), after PCI (T1), 24 h (T2) and 2 weeks (T3) after PCI. The outcomes were compared between the two groups, and compared with those obtained from 20 healthy persons set as the normal control. RESULTS: All the three indices in the two patients' group at T0, T1 and T2 were higher than those in the normal control respectively (P < 0.01), while at T3, the indices in the DHI group were lower than the normal control (P > 0.05). Comparisons between the two patients' group showed that the indices were not different at TO, T1 and T2, but at T3, all were lower in the DHI group than in the control group (P < 0.05, P < 0.01). CONCLUSIONS: Combined conventional therapy with DHI for 2 weeks can significantly reduce the plasma levels of ET-1, sP-sel and hs-CRP in ACS patients after PCI, suggesting that DHI has certain effects in protecting the endothelial function, inhibiting platelet activation and suppressing inflammatory reaction.
RCT Entities:
OBJECTIVE: To observe the effect and explore the action mechanism of Danhong Injection (DHI) on serum levels of endothelin-1 (ET-1), soluble P-selectin (sP-sel) and high sensitivity C-reactive protein (hs-CRP) in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). METHODS: Seventy ACS patients scheduled to receive PCI were assigned to two groups. Around PCI, the 34 patients in the control group were treated with conventional therapy and the 36 in the DHI group treated with conventional therapy combined with DHI treatment given from the day of PCI to the 14th day after operation at the dose of 40 mL per day by dissolving in 250 mL of 5% glucose for venous dripping. Plasma levels of ET-1, sP-sel and hs-CRP were detected using ELISA at various time points: before PCI (T0), after PCI (T1), 24 h (T2) and 2 weeks (T3) after PCI. The outcomes were compared between the two groups, and compared with those obtained from 20 healthy persons set as the normal control. RESULTS: All the three indices in the two patients' group at T0, T1 and T2 were higher than those in the normal control respectively (P < 0.01), while at T3, the indices in the DHI group were lower than the normal control (P > 0.05). Comparisons between the two patients' group showed that the indices were not different at TO, T1 and T2, but at T3, all were lower in the DHI group than in the control group (P < 0.05, P < 0.01). CONCLUSIONS: Combined conventional therapy with DHI for 2 weeks can significantly reduce the plasma levels of ET-1, sP-sel and hs-CRP in ACS patients after PCI, suggesting that DHI has certain effects in protecting the endothelial function, inhibiting platelet activation and suppressing inflammatory reaction.